Phase Ⅲ Clinical Study of Quadrivalent Influenza Virus Split Vaccine

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
A randomized, blind, positive vaccine control trial was designed.A total of 2550 subjects aged 6-35 months were randomly assigned to the low dose (0.25ml/ dose) group, the high dose (0.5ml/ dose) group and the control group in a ratio of 1:1:1. They were inoculated with 2 doses of quadrivalent influenza virus split vaccine (experimental vaccine or control vaccine) at 0 and 28 days of immunization program to observe the Immunogenicity and safety.
Epistemonikos ID: d0d7684fee5e10c1e94f3aad86718a460e509cd9
First added on: May 14, 2024